Phaseline

Targets › IL1B

IL1B (Interleukin-1 beta): drug programs, companies and trials

9 programs from 9 companies in 17 trials: 12 Phase 2, 2 Phase 3, 2 Phase 1, 1 Phase 4; Oncology, Immunology, Hematology; next expected readout Dec 2026.

Potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. (UniProt, P01584)

Open in Phaseline: the race on IL1B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese SLE Treatment And Research GroupFirsekibart
Anti-IL-1β monoclonal antibody
IL1BPhase 4Lupus Erythematosus, SystemicDec 2027
AbbVieLutikizumab
Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor
IL1A, IL1BPhase 3Hidradenitis Suppurativa; Rheumatoid Arthritis; Atopic Dermatitis; Ulcerative Colitis …Dec 2026
University Hospital, Basel, SwitzerlandCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 3Postprandial Hypoglycemia–
M.D. Anderson Cancer CenterCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 2Chronic Myelomonocytic Leukemia; Lung CarcinomaDec 2026
John MascarenhasCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 2Primary MyelofibrosisJul 2027
Uma BorateCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 2Clonal Cytopenia of Undetermined SignificanceDec 2028
Massachusetts General HospitalCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 2Vascular InflammationJan 2029
NYU Langone HealthCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 1Pancreatic Cancer–
H. Lee Moffitt Cancer Center and Research InstituteCanakinumab
Interleukin-1 beta inhibitor
IL1BPhase 1Myelodysplastic Syndromes–

Conditions

Hidradenitis Suppurativa (3) Vascular Inflammation (1) Rheumatoid Arthritis (1) Atopic Dermatitis (1) Ulcerative Colitis (1) Psoriatic Arthritis (1) Crohn's Disease (1) Pancreatic Cancer (1) Primary Myelofibrosis (1) Lupus Erythematosus, Systemic (1) Chronic Myelomonocytic Leukemia (1) Lung Carcinoma (1)

Modalities

antibody (7), mixed (2)

Companies

Massachusetts General Hospital (1) AbbVie (1) NYU Langone Health (1) John Mascarenhas (1) Chinese SLE Treatment And Research Group (1) M.D. Anderson Cancer Center (1) H. Lee Moffitt Cancer Center and Research Institute (1) University Hospital, Basel, Switzerland (1) Uma Borate (1)

Related targets

IL1A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.